| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.5 | -2.7 |
| EPS (diluted, $ a share) | $-1.09 | $-1.55 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: INTS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Intensity Therapeutics, Inc.: key numbers
- Share price
- $3.07Close, Nov 16
- Market cap
- $10.1M
- Shares outstanding
- 3.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Intensity Therapeutics, Inc.
All →Intensity Therapeutics Earnings Call: Key Takeaways
Intensity Therapeutics is restarting Phase 3 and Phase 2 trials after funding-related pauses, but remains severely capital-constrained with only $8.5 million in cash, making future enrollment timelines entirely dependent on successful capital raises.
- Call
- Nov 5, 2026, 8:00 AM ET
Intensity Therapeutics Business Update
Intensity Therapeutics reported its Q3 2026 financial results and provided an operational update on its clinical pipeline, including the resumption of patient enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and the Phase 2 INVINCIBLE-4 triple-negative breast cancer study. The company ended the quarter with $8.5 million in cash and cash equivalents.